Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50

　　1.Disease and Molecular Selection

　　Stage III colon cancer means radical resection of the primary tumor with positive regional nodes and no distant metastasis.Deficient mismatch repair(dMMR)usually coincides with microsatellite instability-high(MSI-H);lost MMR proteins permit replication errors to accumulate,raising neoantigen load and PD-L1 checkpoint sensitivity.Confirm dMMR by IHC for MLH1,MSH2,MSH6,PMS2,supplemented by MSI or sequencing when needed.This adjuvant immuno-chemotherapy pathway applies to stage III dMMR colon adenocarcinoma;rectal cancer,stage II,pMMR/MSS,unresected or metastatic disease are outside the default indication.

　　2.FDA Scope and Formulations

　　On October 8,2026,FDA approved atezolizumab(Tecentriq)with fluoropyrimidine and oxaliplatin as adjuvant therapy for fully resected stage III dMMR colon cancer in patients aged 2 years and older.Tecentriq Hybreza(atezolizumab and hyaluronidase-tqjs)subcutaneous was simultaneously approved with the same chemotherapy class but only for patients aged 12 or older and weighing at least 40kg;below age 12 or below 40kg subcutaneous dosing is not established,so use IV dosing under specialty guidance.

　　Exclude uncontrolled active autoimmunity,significant organ dysfunction,prior severe checkpoint toxicity,residual gross disease,pregnancy or breastfeeding unless a formal risk-benefit plan exists.

　　3.ATOMIC Key Data

　　ATOMIC(NCT02912559)was multicenter,randomized,open-label,active-controlled phase 3 in resected stage III dMMR colon cancer,about 712 adults and a small number of pediatric patients,1:1.The experimental arm received atezolizumab plus mFOLFOX6(oxaliplatin,leucovorin,5-FU)for 12 cycles followed by atezolizumab monotherapy for about 6 months;the control arm received mFOLFOX6 alone for 12 cycles.The primary endpoint was disease-free survival by independent or investigator assessment.

　　Results:DFS hazard ratio 0.50(95%CI 0.35–0.73,P=0.0001);median DFS was not reached in either arm.Published summaries report approximately 86.4%vs 76.6%three-year DFS.The combination reduced relapse,second primary,or death risk by about half in the studied population,but overall survival was immature and should not be presented as confirmed survival benefit or cure.Grade 3–4 neutropenia and immune-related colitis/hepatitis require active recording.

　　4.Dosing Administration

　　Adult IV atezolizumab:840mg every 2 weeks,1200mg every 3 weeks,or 1680mg every 4 weeks.Give with mFOLFOX6 for about 6 months,then atezolizumab alone for about 6 months or until recurrence/unacceptable toxicity.Pediatric weight-based:10mg/kg up to 840mg every 2 weeks,or 15mg/kg up to 1200mg every 3 weeks,same chemo-to-immunology sequence.Subcutaneous Hybreza for eligible age/weight:15mL containing 1875mg atezolizumab and 30,000 units hyaluronidase every 3 weeks,6 months with chemotherapy then 6 months alone.Do not switch IV and subcutaneous by volume equivalence;recalculate exposure when changing formulation.

　　mFOLFOX6 follows institutional oxaliplatin,leucovorin,bolus/infusional 5-FU rules;cycle number,delay,and reduction depend on marrow recovery,neuropathy,hepatic/renal function.During the immunotherapy-maintenance phase,stop cytotoxic chemotherapy unless a new indication appears.

　　5.Safety and Monitoring

　　Atezolizumab blocks PD-L1 and restores T-cell activity but can cause immune-related adverse events:pneumonitis(cough,dyspnea,hypoxia),hepatitis(ALT/AST/bilirubin rise,jaundice),colitis(diarrhea,abdominal pain,hematochezia),endocrinopathies(hypo-/hyperthyroidism,hypophysitis,adrenal insufficiency,hyperglycemia),plus dermatitis,nephritis,myocarditis,and infusion reactions.Manage by CTCAE grade—observe grade 1,hold and consider steroids for grade 2,stop and give specialist steroids/immunosuppression for grade 3–4;seek care immediately for jaundice,dyspnea,persistent diarrhea,or altered mental status.

　　Chemotherapy overlap adds oxaliplatin peripheral sensory neuropathy aggravated by cold,5-FU/leucovorin myelosuppression(neutropenia,anemia,thrombocytopenia),nausea,mucositis,and diarrhea.Monitor CBC,liver/renal panel,electrolytes,and oxaliplatin neuropathy scores.Infection and febrile neutropenia risk rise with combo therapy;use institutional prophylaxis.For people with reproductive potential,perform pregnancy testing and use contraception per label;avoid or stop breastfeeding.

　　6.Adjuvant Pathway Value

　　The approval moves PD-L1 blockade into stage III dMMR colon adjacency after surgery:suitable for fully resected,MMR-confirmed patients without severe autoimmunity/organ limits who accept 6–12 months immunotherapy.Choice versus chemo-only,neoadjuvant immunotherapy,or shorter chemotherapy should weigh N stage,T4 disease,obstruction/perforation history,age tolerance,neuropathy concern,and later metastatic options.Do not decide by stage alone and do not promise zero recurrence from the 50%risk reduction.